

# Francisco Jorquera Plaza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3257070/publications.pdf>

Version: 2024-02-01

57  
papers

2,464  
citations

331259

21  
h-index

205818

48  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. <i>Gut</i> , 2022, 71, 2138-2140.	6.1	9
2	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	1.4	19
3	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
4	Long-Term Effects of Bariatric Surgery on Gut Microbiota Composition and Faecal Metabolome Related to Obesity Remission. <i>Nutrients</i> , 2021, 13, 2519.	1.7	27
5	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 519-530.	1.9	17
6	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
7	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	1.8	59
8	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 397-411.	0.1	7
9	Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1800930.	1.5	71
10	Optimizaci3n en el abordaje multidisciplinar del paciente con hepatitis C en la era de los antivirales de acci3n directa. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2019, 42, 8-13.	0.2	0
11	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
12	Enfermedad hep3tica por alcohol. Gu3as de pr3ctica cl3nica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2019, 42, 657-676.	0.2	12
13	An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 275-282.	0.1	41
14	Linitis plastica of the colon due to metastases of invasive lobular breast carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 326-328.	0.1	1
15	Serrated Lesions in patients with Inflammatory Bowel Disease.. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 400-402.	0.1	0
16	Nuevas terapias en la enfermedad celiaca y sus complicaciones. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2018, 41, 191-204.	0.2	11
17	Documento de consenso. Manejo de la enfermedad hep3tica grasa no alcoh3lica (EHGNA). Gu3a de pr3ctica cl3nica. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2018, 41, 328-349.	0.2	71
18	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83

#	ARTICLE	IF	CITATIONS
19	Hepatitis aguda secundaria a megadosis de metilprednisolona intravenosa. Gastroenterología Y Hepatología, 2018, 41, 508-509.	0.2	1
20	New coeliac disease treatments and their complications. Gastroenterología Y Hepatología (English) 10 (2016) 100-106	0.0	6
21	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clinical Gastroenterology and Hepatology, 2017, 15, 945-949.e1.	2.4	22
22	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology, 2017, 66, 1138-1148.	1.8	159
23	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2017, 24, 226-237.	1.0	22
24	Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World Journal of Gastroenterology, 2017, 23, 7459-7469.	1.4	8
25	Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy. European Journal of Gastroenterology and Hepatology, 2016, 28, 305-312.	0.8	9
26	Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World Journal of Gastroenterology, 2015, 21, 9163.	1.4	10
27	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-486.	0.6	1
28	Análisis descriptivo de los hallazgos endoscópicos en pacientes con antecedentes familiares de cáncer colorrectal. Revista De Gastroenterología De México, 2015, 80, 192-197.	0.4	0
29	Barriers to HCV treatment in the era of triple therapy: a prospective multicentred study in clinical practice. Liver International, 2015, 35, 401-408.	1.9	16
30	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. Gastroenterología Y Hepatología, 2014, 37, 1-8.	0.2	2
31	Modulation of PI3K-LXR-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Laboratory Investigation, 2014, 94, 262-274.	1.7	49
32	P1041 TENOFOVIR MONOTHERAPY VERSUS LAMIVUDINE PLUS ADEFOVIR IN LAMIVUDINE-FAILURE PATIENTS RESCUED WITH LAMIVUDINE PLUS ADEFOVIR COMBINATION: INTERIM ANALYSIS OF THE TENOSIMP-B CLINICAL TRIAL. Journal of Hepatology, 2014, 60, S422.	1.8	1
33	Liver X receptor-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Laboratory Investigation, 2012, 92, 1191-1202.	1.7	50
34	Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus. Journal of Pineal Research, 2011, 50, 38-45.	3.4	77
35	Signaling pathways involved in liver injury and regeneration in rabbit hemorrhagic disease, an animal model of virally-induced fulminant hepatic failure. Veterinary Research, 2010, 41, 02.	1.1	35
36	Primary liver carcinoid tumour with a Zollinger Ellison syndrome - an unusual diagnosis: a case report. Cases Journal, 2009, 2, 6346.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. <i>Journal of Pineal Research</i> , 2008, 45, 532-540.	3.4	189
38	Malignant gastrointestinal obstruction: endoscopic stenting versus surgical palliation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2006, 20, 1083-1087.	1.3	77
39	Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 547-554.	1.4	31
40	Effects of Parenteral Nutrition Supplemented with Alanyl-L-Glutamine on Nutrition Status in Rats. <i>Journal of Parenteral and Enteral Nutrition</i> , 2005, 29, 262-265.	1.3	3
41	Severe Cholestasis and Acute Renal Failure Related to Rofecoxib. <i>American Journal of Gastroenterology</i> , 2004, 99, 1622-1623.	0.2	6
42	Rabbit hemorrhagic viral disease: Characterization of a new animal model of fulminant liver failure. <i>Translational Research</i> , 2003, 141, 272-278.	2.4	55
43	TNP-470 Inhibits Oxidative Stress, Nitric Oxide Production and Nuclear Factor Kappa B Activation in a Rat Model of Hepatocellular Carcinoma. <i>Free Radical Research</i> , 2003, 37, 841-848.	1.5	22
44	Caspase Inhibition Does Not Protect Against Liver Damage in Hemorrhagic Shock. <i>Shock</i> , 2003, 19, 33-37.	1.0	40
45	An uncommon association of abdominal vascular compression syndromes: Dumbbar and Nutcracker. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1151-1153.	0.8	7
46	Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy. <i>American Journal of Gastroenterology</i> , 2001, 96, 2456-2461.	0.2	5
47	Effects of parenteral nutrition supplemented with glutamine or glutamine dipeptides on liver antioxidant and detoxication systems in rats. <i>Nutrition</i> , 2000, 16, 125-128.	1.1	34
48	Endoscopic transpapillary drainage of an infected pancreatic fluid collection in pancreas divisum. <i>Digestive Diseases and Sciences</i> , 2000, 45, 237-241.	1.1	3
49	Physical exercise and improvement of liver oxidative metabolism in the elderly. <i>European Journal of Applied Physiology and Occupational Physiology</i> , 2000, 81, 62-66.	1.2	18
50	Endoscopic Ultrasonography in The Diagnosis of Aorto-esophageal Fistula. <i>American Journal of Gastroenterology</i> , 2000, 95, 1374-1375.	0.2	1
51	Liver blood flow changes during laparoscopic surgery in pigs. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 1999, 13, 668-672.	1.3	48
52	The Effect of Age and Sex on Metabolism and Urinary Excretion of Antipyrine. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 1998, 53A, M14-M19.	1.7	6
53	Influence of nutrition on liver oxidative metabolism. <i>Nutrition</i> , 1996, 12, 442-447.	1.1	23
54	Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1996, 15, 7-11.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Effects of Aging on Antipyrine Clearance: Predictive Factors of Metabolizing Capacity. Journal of Clinical Pharmacology, 1995, 35, 895-901.	1.0	8
56	Assessment of antipyrine kinetics from saliva or plasma: influence of age. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 1141-1145.	1.4	8
57	Antipyrine Clearance in Surgical Patients Maintained on Hypocaloric Peripheral Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 1994, 18, 544-548.	1.3	6